Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

October 21, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **ENDO PHARMA LLC**

2. Issuer Name and Ticker or Trading

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to

Issuer

Director

(Check all applicable)

(Last)

(First)

(Street)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 10/18/2005

Officer (give title below)

_X__ 10% Owner __ Other (specify

320 PARK AVENUE

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NEW YORK, NY 10022

(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially O							lly Owned
2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	(D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Code V	Amount	or	Price	Transaction(s) (Instr. 3 and 4)		
10/18/2005		X	666	D	\$ 2.42	22,247,957	D	
10/18/2005		X	6,379	D	\$ 2.42	22,241,578	D	
10/18/2005		X	2,257	D	\$ 2.42	22,239,321	D	
	2. Transaction Date (Month/Day/Year) 10/18/2005	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 10/18/2005	2. Transaction Date 2A. Deemed 3. Transaction Date, if any (Month/Day/Year) (Month/Day/Year) Code (Instr. 8) Code V 10/18/2005 X	2. Transaction Date (Month/Day/Year)	2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and Code V Amount (D) 10/18/2005 X 666 D	2. Transaction Date (Month/Day/Year)	2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Following Reported Transaction(s) (Instr. 3 and 4) 10/18/2005 X 666 D \$ 2.42 22,247,957	2. Transaction Date (Month/Day/Year) 3.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Common Stock, par value \$.01 per share	10/18/2005	X	6,520	D	\$ 2.42	22,232,801	D
Common Stock, par value \$.01 per share	10/18/2005	X	957	D	\$ 2.42	22,231,844	D
Common Stock, par value \$.01 per share	10/18/2005	X	2,555	D	\$ 3	22,229,289	D
Common Stock, par value \$.01 per share	10/18/2005	X	6,928	D	\$ 3	22,222,361	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number tion Derivative Securities) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercise Expiration Date (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	10/18/2005		X		666	10/13/2005	08/26/2007	Common Stock	666
Call Option (obligation to sell)	\$ 2.42	10/18/2005		X		6,379	10/13/2005	08/26/2007	Common Stock	6,379
Call Option (obligation to sell)	\$ 2.42	10/18/2005		X		2,257	10/13/2005	08/26/2007	Common Stock	2,257

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Call Option (obligation to sell)	\$ 2.42	10/18/2005	X	6,520	10/13/2005	08/26/2007	Common Stock	6,520
Call Option (obligation to sell)	\$ 2.42	10/18/2005	X	957	10/13/2005	08/26/2007	Common Stock	957
Call Option (obligation to sell)	\$ 3	10/18/2005	X	2,555	10/13/2005	08/26/2007	Common Stock	2,555
Call Option (obligation to sell)	\$ 3	10/18/2005	X	6,928	10/13/2005	08/26/2007	Common Stock	6,928

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
ENDO PHARMA LLC 320 PARK AVENUE		X					
NEW YORK, NY 10022							

Signatures

/s/ Jeffrey R. Black Chief Financial
Officer 10/21/2005

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).